Institution | Regimen | Receptor target | Setting | Results/Status | Trial ID |
---|---|---|---|---|---|
University of North Carolina | Erlotinib | EGFR | Neoadjuvant | Completed. Well tolerated. 35% (7/20) histologic downstaging preoperatively [26]. | |
University of North Carolina | Erlotinib | EGFR | Neoadjuvant + Adjuvant | Ongoing | NCT00380029 |
MDACC | Erlotinib | EGFR | Neoadjuvant | Ongoing | NCT00749892 |
Dendreon | DN24-02 | HER2R | Adjuvant | Ongoing. Updated results: 75% of 226 patients had HER2 expression in primary tumor, 84% in lymph nodes. APC activation for all 30 patients who have received 3 infusions of drug [27]. | NCT01353222 |
Medical University of South Carolina | Bevacizumab + GC and Bevacizumab + Paclitaxel# | VEGFR-A | Neoadjuvant + Adjuvant | Ongoing. Preliminary results: 42% (5/12) postoperative complication rate. 31% (4/13) downstaging preoperatively [28]. | NCT00268450 |
MDACC | Bevacizumab + MVAC | VEGFR-A | Neoadjuvant | Ongoing | NCT00506155 |
FTRC | Sorafenib + GC | VEGFR + PDGFR* | Neoadjuvant | Unknown. | NCT01222676 |
US Oncology | Sunitinib + GC | VEGFR + PDGFR* | Neoadjuvant | Terminated early due to patient toxicity. Only 9 MIBC patients studied for neoadjuvant therapy [29]. | |
MSKCC | Sunitinib + GC | VEGFR + PDGFR* | Neoadjuvant | Completed early due to limited study accrual. pT0 rate was low with combination [30]. | NCT00847015 |
CCCC | Sunitinib | VEGFR + PDGFR* | Neoadjuvant | Completed, Results Unreported | NCT00526656 |
Hoosier Oncology Group | Dasatinib | BCR/Abl^ | Neoadjuvant | Completed. Well tolerated. Follow-up pathology study: SFK expression downregulated in 77% (14/18) of patients [31, 32]. | NCT00706641 |
University of Michigan | Sunitinib | VEGFR + PDGFR* | Adjuvant | Terminated due to poor accrual | NCT01042795 |
Hoosier Oncology Group | Sunitinib + GC | VEGFR + PDGFR* | Neoadjuvant | Terminated due to patient toxicities | NCT00859339 |